A Novel Design for Investigating Cell Deconvolution Methods for Tumor Microenvironment
ISEF · 2019 Computational Biology and Bioinformatics
Overview
Precision medicine, or personalized medicine, is the most promising direction for treating complex diseases, such as cancer. The deadliest solid cancer, Pancreatic Ductal Adenocarcinoma (PDAC), has a 5-year survival rate of 4%, and hope for finding viable treatment plans to increase this survival rate lies in precision medicine. The execution of such a treatment plan relies on the knowledge of genetic signatures of the pancreatic tumor cells. However, isolation of these tumor cells is not a simple task: they exist in a complex tumor microenvironment along with many other cell types. Learning the composition of cell types in a tumor sample and the genetic signatures of the individual cell types are crucial. This can be done with deep learning methods, which digitally decompose bulk tumor sample data into cell-type-specific information. Yet, a major issue is the lack of “gold standard” benchmarking data sets that can be used to evaluate and compare the accuracy of digital decomposition methods. Existing data have limited sample size and between-patient variability, and thus do not truly represent the patient population. This work proposes a novel design to create synthetic data to investigate deep learning cell deconvolution methods so that their accuracy for predicting cell-specific genetic signatures can be evaluated. The design is applied to PDAC with the hope that accurately obtained genetic signatures will enable the initiation of a precision medicine treatment plan for individual patients. This work can also contribute to improved prognosis and treatment of other cancers and complex diseases in general.
Awards (1)
- Second Award of $1,500 $1,500
Competition history
- ISEF 2019
Resources
Related projects
ISEF · 2020
PANCREAS.AI: Novel Deep Learning-based Screening Towards Precision Applications for Pancreatic Cancer
ISEF · 2026
Toward Precision Oncology: Integrating Clinical and Mutational Data to Predict Pancreatic Cancer Survival Using Machine Learning
ISEF · 2026
Integrative Multi-Omic Data Profiling of Pancreatic Ductal Adenocarcinoma for Identification of Oncofetal Targets and Designing a Novel Bispecific Antibody-Drug Conjugate
ISEF · 2025
Decoding PDAC: A scRNA-seq Omics Analysis to Unveil and Inhibit Key Protein Using a Novel in-silico, Structure-Based Drug Design Pipeline
Closest projects by meaning, across every fair and year in the corpus.
Source: Regeneron International Science and Engineering Fair